)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Scandinavian Real Heart
Scandinavian Real Heart (HEART) investor relations material
Scandinavian Real Heart H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary26 Aug, 2026
Executive summary
Achieved key operational milestones, including ethical approval for chronic in vivo studies and continued transition to new manufacturing facilities to support future clinical activities.
Board adopted a new strategic goal to be ready for first-in-human implantation of the artificial heart in February 2028.
Strengthened scientific validation with a peer-reviewed study showing significantly lower hemolysis compared to a leading artificial heart.
Enhanced intellectual property position with new patents granted in Europe, China, Australia, and India, protecting core technology and adaptive control systems.
Successfully completed a rights issue, raising approximately SEK 49 million before issue costs to support ongoing development.
Financial highlights
Operating income for H1 2026 was SEK 86,587, similar to H1 2025.
Loss after financial items for H1 2026 was SEK -23.96 million, compared to SEK -18.63 million in H1 2025.
Cash and cash equivalents at period end were SEK 40.0 million, up from SEK 27.9 million at H1 2025.
Equity/assets ratio improved to 91% from 85% year-over-year.
Earnings per share for H1 2026 was SEK -2.82, compared to SEK -4.23 in H1 2025.
Outlook and guidance
Focus remains on achieving readiness for first-in-human implantation by February 2028.
Six-month full-system reliability demonstration expected to complete in Q1 2027.
Continued emphasis on advancing preclinical program, manufacturing readiness, and data generation for clinical studies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Scandinavian Real Heart
- No FY2025 dividend; share-issue authority approved to increase financial flexibility.HEART
AGM 2026 - Preclinical progress, patent expansion, and strong financing position clinical readiness for 2026.HEARTQ4 2025
- Jan. 13–27 rights issue funds Realheart TAH development and regulatory steps.HEARTStatus update
- Patent wins, capital raises, and scientific validation drive progress despite ongoing losses.HEARTQ2 2025
- Preclinical progress, new funding, and strategic alliances drive Realheart toward clinical trials.HEARTQ3 2024
- SEK 24.3 million raised to fund Realheart's artificial heart preclinical program, cash runway to Q4 2025.HEARTQ2 2024
- SEK 30.2 million raised as Realheart advances artificial heart to clinical trial readiness.HEARTQ1 2025
- Key preclinical progress and FDA HUD status position Realheart for clinical trial initiation.HEARTQ4 2024
Next Scandinavian Real Heart earnings date
H2 202619 Feb, 2027
Scandinavian Real Heart
Next Scandinavian Real Heart earnings date
H2 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Scandinavian Real Heart AB is a medical technology company based in Sweden that specializes in the development of artificial heart devices. The company's primary product is a heart pump designed to mimic the body's natural circulatory system, serving as a temporary solution for patients awaiting heart transplants. The artificial heart, known as the Realheart TAH, aims to replicate the human heart's function by providing a pulsatile blood flow, which is crucial for maintaining organ health during the transplant waiting period. The company is headquartered in Västerås, Sweden, and its shares are listed on the Nasdaq Stockholm.